Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections.
暂无分享,去创建一个
Anthony Rhodes | Bharat Jasani | R. Nicholson | A. Douglas-Jones | B. Jasani | P. Barrett-Lee | A. Rhodes | Robert Nicholson | Anthony Douglas-Jones | Peter J Barrett-Lee | Susan Wozniak | Julie Gee | J. Gee | S. Wozniak
[1] J. Coindre,et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.
[2] J. Jacquemier,et al. Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. , 1986, Cancer research.
[3] R. Ravid,et al. Activation of the human supraptic and paraventricular nucleus neurons with aging and in Alzheimer's disease as judged from increasing size of the Golgi apparatus , 1993, Brain Research.
[4] M Bibbo,et al. Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. , 1987, Analytical and quantitative cytology and histology.
[5] R. Blamey. Guidelines on endocrine therapy of breast cancer EUSOMA. , 2002, European journal of cancer.
[6] A. Serizawa,et al. Heat‐induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin‐fixed, paraffin‐embedded sections , 1994, Pathology international.
[7] S. Pileri,et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods , 1997, The Journal of pathology.
[8] B. Jasani,et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.
[9] D. Barnes,et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.
[10] O. Petersen,et al. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. , 1987, Cancer research.
[11] P. Chambon,et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. , 1991, Cancer research.
[12] A. Howell,et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.
[13] L. Bobrow,et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.
[14] J. Sloane,et al. Oestrogen receptor expression in the normal and pre‐cancerous breast , 1999, The Journal of pathology.
[15] S R Shi,et al. DEVELOPMENT OF AN OPTIMAL PROTOCOL FOR ANTIGEN RETRIEVAL: A ‘TEST BATTERY’ APPROACH EXEMPLIFIED WITH REFERENCE TO THE STAINING OF RETINOBLASTOMA PROTEIN (pRB) IN FORMALIN‐FIXED PARAFFIN SECTIONS , 1996, The Journal of pathology.
[16] N. Piggott,et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.
[17] A. Howell,et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast , 1991, International journal of cancer.
[18] D. Barnes,et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.
[19] D. Sgoutas,et al. Immunohistochemical progesterone receptor assay. Measurement by image analysis. , 1991, American journal of clinical pathology.
[20] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D H Wright,et al. Tissue preparation for immunocytochemistry. , 1997, Journal of clinical pathology.
[22] J. Demongeot,et al. Image cytometry of estrogen receptors in breast carcinomas. , 1988, Cytometry.
[23] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] Immunohistochemical determination of nuclear antigens by colour image analysis: application for labelling index, estrogen and progesterone receptor status in breast cancer. , 1994, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[25] Clive R. Taylor,et al. Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin-fixed tissue sections , 1998 .
[26] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] I. Ellis,et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.